Abstract
Foot-and-mouth disease virus (FMDV) is a highly contagious pathogen that poses a significant threat to the global livestock industry. However, specific antiviral treatments against FMDV are currently unavailable. This study aimed to evaluate the antiviral activity of anticancer drugs, including kinase and non-kinase inhibitors against FMDV replication in BHK-21 cells. Sorafenib, a multi-kinase inhibitor, demonstrated a significant dose-dependent reduction in FMDV replication. It exhibited a half maximal effective concentration (EC50) value of 2.46 µM at the pre-viral entry stage and 2.03 µM at the post-viral entry stage. Further intracellular assays revealed that sorafenib effectively decreased 3Dpol activity with a half maximal inhibitory concentration (IC50) of 155 nM, while not affecting 3Cpro function. The study indicates that sorafenib influences host protein pathways during FMDV infection, primarily by potentiating the c-RAF canonical pathway and AKT/PI3K pathway. Molecular docking analysis demonstrated specific binding of sorafenib to the active site of FMDV 3Dpol, interacting with crucial catalytic residues, including D245, D338, S298, and N307. Additionally, sorafenib exhibited significant binding affinity to the active site motifs of cellular kinases, namely c-RAF, AKT, and PI3K, which play critical roles in the viral life cycle. The findings suggest that sorafenib holds promise as a therapeutic agent against FMDV infection. Its mechanism of action may involve inhibiting FMDV replication by reducing 3Dpol activity and regulating cellular kinases. This study provides insights for the development of novel therapeutic strategies to combat FMDV infections.
This is a preview of subscription content, access via your institution.
Data availability
Datasets supporting the conclusions of this article are included within the article and its supplementary files. If necessary, further data generated during the current study can be available from the corresponding author on reasonable request.
References
Belsham GJ (2020) Towards improvements in foot-and-mouth disease vaccine performance. Acta Vet Scand 62:20. https://doi.org/10.1186/s13028-020-00519-1
Benedict A, Bansal N, Senina S et al (2015) Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection. Front Microbiol 6:1–14. https://doi.org/10.3389/fmicb.2015.00676
Booth L, Shuch B, Albers T et al (2016) Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function. Oncotarget 7:12975–12996. https://doi.org/10.18632/oncotarget.7349
Brahms A, Mudhasani R, Pinkham C et al (2017) Sorafenib impedes rift valley fever virus egress by inhibiting valosin-containing protein function in the cellular secretory pathway. J Virol 91:e00968-e1017. https://doi.org/10.1128/JVI.00968-17
BĂ¼rckstĂ¼mmer T, Kriegs M, Lupberger J et al (2006) Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication. FEBS Lett 580:575–580. https://doi.org/10.1016/j.febslet.2005.12.071
Carrillo C, Tulman ER, Delhon G et al (2005) Comparative genomics of foot-and-mouth disease virus. J Virol 79:6487–6504. https://doi.org/10.1128/jvi.79.10.6487-6504.2005
Carrillo C, Tulman ER, Delhon G et al (2006) High throughput sequencing and comparative genomics of foot-and-mouth disease virus. Dev Biol (Basel) 126:23–30. https://doi.org/10.1128/jvi.79.10.6487
Chen S, Liu G, Chen J et al (2019) Ponatinib protects mice from lethal influenza infection by suppressing cytokine storm. Front Immunol 10. https://doi.org/10.3389/fimmu.2019.01393
Curtin N, BĂ¡nyai K, Thaventhiran J et al (2020) Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome? Br J Pharmacol 177:3635–3645. https://doi.org/10.1111/bph.15137
Dallakyan S, Olson AJ (2015) Small-molecule library screening by docking with PyRx. In: Hempel JE, Williams CH, Hong CC (eds) Chemical Biology: Methods and Protocols, Methods in Molecular Biology. Springer New York, New York, NY, pp 243–250.
Descamps V, Helle F, Louandre C et al (2015) The kinase-inhibitor sorafenib inhibits multiple steps of the hepatitis C virus infectious cycle in vitro. Antiviral Res 118:93–102. https://doi.org/10.1016/j.antiviral.2015.03.012
Dyall J, Coleman CM, Hart BJ et al (2014) Repurposing of clinically developed drugs for treatment of middle east respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 58:4885–4893. https://doi.org/10.1128/AAC.03036-14
Ferrer-Orta C, Arias A, Perez-Luque R et al (2004) Structure of foot-and-mouth disease virus RNA-dependent RNA polymerase and its complex with a template-primer RNA. J Biol Chem 279:47212–47221. https://doi.org/10.1074/jbc.M405465200
Fry EE, Stuart DI, Rowlands DJ (2005) The structure of foot-and-mouth disease virus. Curr Top Microbiol Immunol 288:71–101. https://doi.org/10.1007/3-540-27109-0_4
Gao M, Duan H, Liu J et al (2014) The multi-targeted kinase inhibitor sorafenib inhibits enterovirus 71 replication by regulating IRES-dependent translation of viral proteins. Antiviral Res 106:80–85. https://doi.org/10.1016/j.antiviral.2014.03.009
GarcĂa M, Cooper A, Shi W et al (2012) Productive replication of ebola virus is regulated by the c-Abl1 tyrosine kinase. Sci Transl Med 4:123ra24. https://doi.org/10.1126/scitranslmed.3003500
Grubman MJ, Baxt B (2004) Foot-and-Mouth Disease. Clin Microbiol Rev 17:465–493. https://doi.org/10.1128/CMR.17.2.465-493.2004
Hatzivassiliou G, Song K, Yen I et al (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464:431–435. https://doi.org/10.1038/nature08833
Himmelsbach K, Sauter D, Baumert TF et al (2009) New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication. Gut 58:1644–1653. https://doi.org/10.1136/gut.2009.182212
Kindrachuk J, Ork B, Hart BJ et al (2015) Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle east respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Chemother 59:1088–1099. https://doi.org/10.1128/AAC.03659-14
Lekcharoensuk P, Wiriyarat W, Petcharat N et al (2012) Cloned cDNA of A/swine/Iowa/15/1930 internal genes as a candidate backbone for reverse genetics vaccine against influenza A viruses. Vaccine 30:1453–1459. https://doi.org/10.1016/j.vaccine.2011.12.109
Lesch M, Luckner M, Meyer M et al (2019) RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals. PLOS Pathog 15:e1007601. https://doi.org/10.1371/journal.ppat.1007601
Lin K, Lin J, Wu W-I et al (2012) An ATP-Site on-off switch that restricts phosphatase accessibility of Akt. Sci Signal 5:ra37–ra37. https://doi.org/10.1126/scisignal.2002618
Liu L, Cao Y, Chen C et al (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851–11858. https://doi.org/10.1158/0008-5472.CAN-06-1377
Lundberg L, Brahms A, Hooper I et al (2018) Repurposed FDA-approved drug sorafenib reduces replication of Venezuelan equine encephalitis virus and other alphaviruses. Antiviral Res 157:57–67. https://doi.org/10.1016/j.antiviral.2018.07.005
Lupberger J, Zeisel MB, Xiao F et al (2011) EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 17:589–595. https://doi.org/10.1038/nm.2341
Michaelis M, Paulus C, Löschmann N et al (2011) The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication. Cell Mol Life Sci 68:1079–1090. https://doi.org/10.1007/s00018-010-0510-8
Miller MS, Schmidt-Kittler O, Bolduc DM et al (2014) Structural basis of nSH2 regulation and lipid binding in PI3Kα. Oncotarget 5:5198–5208. https://doi.org/10.18632/oncotarget.2263
O’Boyle NM, Banck M, James CA et al (2011) Open Babel: An open chemical toolbox. J Cheminform 3:33. https://doi.org/10.1186/1758-2946-3-33
Raymonda MH, Ciesla JH, Monaghan M et al (2022) Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro. Virology 566:60–68. https://doi.org/10.1016/j.virol.2021.11.008
Sadeghian-Rizi S, Khodarahmi G, Sakhteman A et al (2018) Synthesis and characterization of some novel diaryl urea derivatives bearing quinoxalindione moiety. Res Pharm Sci 13:82. https://doi.org/10.4103/1735-5362.220971
Schor S, Einav S (2018) Repurposing of kinase inhibitors as broad-spectrum antiviral drugs. DNA Cell Biol 37:63–69. https://doi.org/10.1089/dna.2017.4033
Semkum P, Kaewborisuth C, Thangthamniyom N et al (2021) A novel plasmid DNA-based foot and mouth disease virus minigenome for intracytoplasmic mRNA production. Viruses 13:1047. https://doi.org/10.3390/v13061047
Stirling DR, Carpenter AE, Cimini BA (2021) Cell Profiler Analyst 3.0: accessible data exploration and machine learning for image analysis. Bioinformatics 37:3992–3994. https://doi.org/10.1093/bioinformatics/btab634
Strobelt R, Adler J, Paran N et al (2022) Imatinib inhibits SARS-CoV-2 infection by an off-target-mechanism. Sci Rep 12:5758. https://doi.org/10.1038/s41598-022-09664-1
Theerawatanasirikul S, Semkum P, Lueangaramkul V et al (2023) Non-nucleoside inhibitors decrease foot-and-mouth disease virus replication by blocking the viral 3Dpol. Viruses 15:124. https://doi.org/10.3390/v15010124
Theerawatanasirikul S, Thangthamniyom N, Kuo C-J et al (2021) Natural phytochemicals, luteolin and isoginkgetin, inhibit 3C protease and infection of FMDV, in silico and in vitro. Viruses 13:2118. https://doi.org/10.3390/v13112118
Theerawatanasirikul S, Lekcharoensuk P (2021) Virtual screening of natural compounds targeting proteases of coronaviruses and picornaviruses. In: Roy K (ed) Methods in Pharmacology and Toxicology. Springer US, New York, NY, pp 661–681
Trott O, Olson AJ (2009) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455–461. https://doi.org/10.1002/jcc.21334
Van Der Linden L, Ulferts R, Nabuurs SB et al (2014) Application of a cell-based protease assay for testing inhibitors of picornavirus 3C proteases. Antiviral Res 103:17–24. https://doi.org/10.1016/j.antiviral.2013.12.012
Vardanyan R, Hruby V (2016) Antiviral Drugs. In: Vardanyan R, Hruby V (eds) Synthesis of Best-Seller Drugs. Elsevier, Boston, pp 687–736
Wilhelm S, Carter C, Lynch M et al (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5:835–844. https://doi.org/10.1038/nrd2130
Wishart DS, Feunang YD, Guo AC et al (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46:D1074–D1082. https://doi.org/10.1093/nar/gkx1037
Yang C-W, Peng T-T, Hsu H-Y et al (2020) Repurposing old drugs as antiviral agents for coronaviruses. Biomed J 43:368–374. https://doi.org/10.1016/j.bj.2020.05.003
Yang H, Rudge DG, Koos JD et al (2013) mTOR kinase structure, mechanism and regulation. Nature 497:217–223. https://doi.org/10.1038/nature12122
Yin P, Kielian M (2021) BHK-21 cell clones differ in chikungunya virus infection and MXRA8 Receptor Expression. Viruses 13:949. https://doi.org/10.3390/v13060949
Yuan Y, Wang X, Li J et al (2022) Single-cell sequencing yields insights in the evolution of foot-and-mouth disease virus persistent infection. Front Cell Infect Microbiol 12:1–14. https://doi.org/10.3389/fcimb.2022.940906
Zell R (2018) Picornaviridae—the ever-growing virus family. Arch Virol 163:299–317. https://doi.org/10.1007/s00705-017-3614-8
Zhang C, Wang X, Wang H et al (2015) Sorafenib inhibits liver cancer growth by decreasing mTOR, AKT, and PI3K expression. J BUON 20:218–222
Acknowledgements
We greatly thank Pongrama Ramasoota at Mahidol University, Thailand; for providing the plasmid expressing scFv-Fc for this study.
Funding
This work was supported by the Thailand Science Research and Innovation (TSRI) (Grant number RTA6280011), Kasetsart University Research and Development Institute (KURDI), (Grant number FF(KU)17.64) and Agricultural Research and Development Agency (Grant number CRP6405031930).
Author information
Authors and Affiliations
Contributions
Conceptualization: Sirin Theerawatanasirikul, Porntippa Lekcharoensuk; Methodology: Sirin Theerawatanasirikul, Varanya Lueangaramkul, Ploypailin Semkum; Data visualization and statistical analysis: Sirin Theerawatanasirikul, Varanya Lueangaramkul; Writing—original draft preparation: Sirin Theerawatanasirikul; Writing—review and editing: Sirin Theerawatanasirikul, Porntippa Lekcharoensuk; Funding acquisition and resources: Porntippa Lekcharoensuk. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Ethics approval
Not applicable as no animal usage in this study.
Competing interests
The authors declare that they have no competing.
Consent for publication
We consent to the publication of the submitted manuscript.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Theerawatanasirikul, S., Lueangaramkul, V., Semkum, P. et al. Antiviral mechanisms of sorafenib against foot-and-mouth disease virus via c-RAF and AKT/PI3K pathways. Vet Res Commun (2023). https://doi.org/10.1007/s11259-023-10211-0
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11259-023-10211-0